Long‐term effects: Galectin‐1 and specific immunotherapy for allergic responses in the intestine

Yang, Litao; Shu, Qinghai; Luo, Xiang‐Qian; Liu, Z.‐Q.; Qiu, Shuqi; Liu, J.‐Q.; Guo, Hua; Li, L.‐J.; Li, M.‐G.; Liu, D.‐B.; Xia, Lixin; Liu, Z.‐G.; Yang, Ping‐Chang

doi:10.1111/all.13256

Cited by 15 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a murine model of oral allergy syndrome, administration of Gal-1 suppressed allergic reaction induced by food allergens by inhibiting IL-4 production, recruitment of mast cells and eosinophils, and synthesis of histamine (41). More recently, Gal-1 has been shown to synergize with allergen-specific immunotherapy, providing long-term benefits in animal models by targeting mast cells and facilitating Treg development (122). Overall, these reports suggest that Gal-1 influences the resolution of allergic reactions and might represent a useful tool for the treatment of allergic diseases.…”

Section: Gal-1 As a Tuner Of Allergic Inflammation And Asthmamentioning

confidence: 99%

Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation

Sundblad

Morosi

Geffner

et al. 2017

The Journal of Immunology

158

136

View full text Add to dashboard Cite

Regulatory signals provide negative input to immunological networks promoting resolution of acute and chronic inflammation. Galectin-1 (Gal-1), a member of a family of evolutionarily conserved glycan-binding proteins, displays broad anti-inflammatory and proresolving activities by targeting multiple immune cell types. Within the innate immune compartment, Gal-1 acts as a resolution-associated molecular pattern by counteracting the synthesis of proinflammatory cytokines, inhibiting neutrophil trafficking, targeting eosinophil migration and survival, and suppressing mast cell degranulation. Likewise, this lectin controls T cell and B cell compartments by modulating receptor clustering and signaling, thus serving as a negative-regulatory checkpoint that reprograms cellular activation, differentiation, and survival. In this review, we discuss the central role of Gal-1 in regulatory programs operating during acute inflammation, autoimmune diseases, allergic inflammation, pregnancy, cancer, and infection. Therapeutic strategies aimed at targeting Gal-1-glycan interactions will contribute to overcome cancer immunosuppression and reinforce antimicrobial immunity, whereas stimulation of Gal-1-driven immunoregulatory circuits will help to mitigate exuberant inflammation.

show abstract

Section: Gal-1 As a Tuner Of Allergic Inflammation And Asthmamentioning

confidence: 99%

Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation

Sundblad

Morosi

Geffner

et al. 2017

The Journal of Immunology

158

136

View full text Add to dashboard Cite

show abstract

“…In addition, rGal-1 did not reduce plasma IgE levels 24 hours after the last OVA challenge in an OVA-induced atopic dermatitis mouse model [13]. However, another line of research related to long-term treatment with rGal-1 and allergen-specific immunotherapy found that rGal-1 markedly decreased the plasma IgE levels in an OVA-induced intestinal allergy mouse model [35]. These differences may suggest that downregulation of IgE by rGal-1 in allergic inflammation was time-dependent.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation

Dai

Wang

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

Galectin-1 (Gal-1) has immunomodulatory activities in various allergic inflammatory disorders, but its potential anti-inflammatory properties on allergic airway diseases have not been confirmed. We explored the pharmacological effects of Gal-1 on the progression of allergic airway inflammation and investigated the underlying mechanism. Female C57BL/6 mice were sensitized on day 0 and challenged with ovalbumin (OVA) on days 14-17 to establish an allergic airway inflammation model. In the challenge phase, a subset of mice was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). We found that rGal-1 inhibited pulmonary inflammatory cell recruitment, mucus secretion, bronchoalveolar lavage fluid (BALF) inflammatory cell infiltration, and cytokine production. The treatment also suppressed the infiltration of eosinophils into the allergic lung as indicated by decreased expression levels of eotaxin and eosinophil peroxidase (EPX). However, only the expression levels of IL-25, neither IL-33 nor TSLP, were significantly decreased in the lung by rGal-1 treatment. These immunomodulatory effects in the allergic lung were correlated with the activation of extracellular signal-regulated kinase (ERK) signaling pathway and downregulation of endogenous Gal-1. In addition, rGal-1 reduced the plasma concentrations of anti-OVA immunoglobulin E (IgE) and IL-17. Our findings suggest that rGal-1 is an effective therapy for allergic airway inflammation in a murine model and may be a potential pharmacological target for allergic airway inflammatory diseases.

show abstract

“…Following our established procedures, an FA mouse model was developed. Briefly, mice were firstly sensitized by subcutaneous injection of 20 μg CT/100 μg OVA at days 1 and 3 of week 0, and then, from week 1 to week 4 mice were gavage‐fed with OVA (1 mg/mouse) and cholera toxin (20 μg/mouse) in 0.1 mL saline once a week.…”

Section: Methodsmentioning

confidence: 99%

“…Food allergy mice were orally challenged with 50 mg OVA/mouse on week 5 and sacrificed next day. The FA relevant response was assessed with our established procedures, including diarrhoea and core temperature, serum levels of specific IgE and mouse mast cell protease‐1 (mMCP1), levels of Th2 cytokines in the intestinal tissue protein extracts and the intestinal epithelial barrier permeability (see below). The experimental procedures can be referred to our publication …”

Section: Methodsmentioning

confidence: 99%

Chimeric specific antigen epitope‐carrying dendritic cells induce interleukin‐17(+) regulatory T cells to suppress food allergy

Xie

et al. 2019

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Food allergies (FAs) affect about 2%-8% of the world's population. FA clinical symptoms vary from slight abdominal discomfort to life-threatening anaphylactic shock. 1 The basic FA pathological changes are Th2 polarization-related inflammation, including the over production of antigen (Ag)-specific IgE, Th2 cytokines (eg interleukin [IL]-4, IL-5 and IL-13), profound infiltration of eosinophils and mast cells in tissues. 2 Th2 cytokines, especially IL-4, induce plasma cells to produce IgE. IgE binds to the high-affinity IgE receptors on the surface Abstract Background: The on-purpose-modulated dendritic cells (DCs) have shown charming effects on restoring immune regulatory functions in subjects with immune diseases. Objective: This study aims to construct DCs carrying chimerical antigen (Ag) peptides (CAP-DCs) to induce interleukin (IL)-17+ inducible Tregs (iTregs) to alleviate food allergy (FA) in a murine model. Methods: In this study, we constructed CAP-DCs. The CAP is a fusion protein, consisting of a segment of recombinant scFv of anti-DEC205 antibody and an ovalbumin (OVA) epitope (IC). A murine OVA-FA model was developed to test the effects of CAP-DCs on suppressing the allergic response in the intestine. Results: The CAP-DCs are characterized as that a complex of scFv-IC is presented on the surface of the cells, moderately express CD80 and CD86 as well as IL-6, IL-23, transforming growth factor (TGF)-β and CCR9. After being passively transferred with CAP-DCs or injection of scFv-IC, Ag-specific IL-17+ Foxp3+ iTregs were induced in the intestinal lamina propria of FA mice. The iTregs showed immune suppressive effects on Ag-specific Th2 response. FA mice were adoptively transferred with the CAP-DCs or scFv-IC injection, which resulted in a significant decrease in the number of Ag-specific Th2 cells and suppression of FA response in an Ag-specific manner. Conclusions and Clinical Relevance: CAP-DCs can ameliorate FA response by inducing Ag-specific IL-17+ Foxp3+ iTregs and suppressing Ag-specific Th2 response. To generate CAP-DCs has the translational potential in the treatment of FA. K E Y W O R D S dendritic cell, epitope, food allergy, immune regulation, immunotherapy

show abstract

Long‐term effects: Galectin‐1 and specific immunotherapy for allergic responses in the intestine

Abstract: Long-term effects of specific immunotherapy on intestinal allergy can be achieved with Gal-1/SIT therapy by inhibiting mast cell activation and facilitating Treg development.

Cited by 15 publications

References 39 publications

Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation

Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation

Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation

Chimeric specific antigen epitope‐carrying dendritic cells induce interleukin‐17(+) regulatory T cells to suppress food allergy

Contact Info

Product

Resources

About